I. Cromwell

发表

‘Real-world’ health care priority setting using explicit decision criteria: a systematic review of the literature

C. Mitton, S. Peacock, I. Cromwell, 2015, BMC Health Services Research.

Health-care practitioners’ preferences for the return of secondary findings from next-generation sequencing: a discrete choice experiment

Y. Bombard, A. Anis, D. Regier, 2020, Genetics in Medicine.

Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada.

S. Peacock, D. Regier, I. Cromwell, 2016, The oncologist.

Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada

S. Peacock, M. Gaudet, C. Aquino-Parsons, 2016, BMC Health Services Research.

The Economic Consequences of Delay in Radiotherapy: An Example in Early Breast Cancer

I. Cromwell, 2015 .

Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada

Heidi Roberts, Don D. Sin, John Yee, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.

K. van der Hoek, S. Peacock, I. Cromwell, 2012, Lung cancer.

A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX) in estrogen receptor positive (ER+) node negative (pN0) breast cancer in academic Canadian centers.

K. Gelmon, S. Peacock, C. Lohrisch, 2012 .

Cost‐effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial

E. Franco, K. van der Hoek, S. Peacock, 2021, Cancer medicine.

A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.

K. Gelmon, S. Peacock, C. Lohrisch, 2013, European journal of cancer.

A time-and-motion approach to micro-costing of high-throughput genomic assays.

D. Scott, J. Connors, S. Ben-Neriah, 2016, Current oncology.

Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60

J. Connors, R. Kridel, C. Steidl, 2022, Cancers.

Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis.

K. van der Hoek, S. Peacock, I. Cromwell, 2016, Current oncology.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis

Stuart Peacock, K. van der Hoek, S. Peacock, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.